BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33405090)

  • 1. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS
    Kenney C; Kunst T; Webb S; Christina D; Arrowood C; Steinberg SM; Mettu NB; Kim EJ; Rudloff U
    Invest New Drugs; 2021 Jun; 39(3):821-828. PubMed ID: 33405090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
    Chung V; McDonough S; Philip PA; Cardin D; Wang-Gillam A; Hui L; Tejani MA; Seery TE; Dy IA; Al Baghdadi T; Hendifar AE; Doyle LA; Lowy AM; Guthrie KA; Blanke CD; Hochster HS
    JAMA Oncol; 2017 Apr; 3(4):516-522. PubMed ID: 27978579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
    Bekaii-Saab T; Phelps MA; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA
    J Clin Oncol; 2011 Jun; 29(17):2357-63. PubMed ID: 21519026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
    Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
    Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
    Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
    Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
    Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
    Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
    N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
    Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
    Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selumetinib in the treatment of non-small-cell lung cancer.
    Bernabé R; Patrao A; Carter L; Blackhall F; Dean E
    Future Oncol; 2016 Nov; 12(22):2545-2560. PubMed ID: 27467210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
    Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
    JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.
    O'Neil BH; Goff LW; Kauh JS; Strosberg JR; Bekaii-Saab TS; Lee RM; Kazi A; Moore DT; Learoyd M; Lush RM; Sebti SM; Sullivan DM
    J Clin Oncol; 2011 Jun; 29(17):2350-6. PubMed ID: 21519015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
    Jain N; Curran E; Iyengar NM; Diaz-Flores E; Kunnavakkam R; Popplewell L; Kirschbaum MH; Karrison T; Erba HP; Green M; Poire X; Koval G; Shannon K; Reddy PL; Joseph L; Atallah EL; Dy P; Thomas SP; Smith SE; Doyle LA; Stadler WM; Larson RA; Stock W; Odenike O
    Clin Cancer Res; 2014 Jan; 20(2):490-8. PubMed ID: 24178622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
    Zaman K; Winterhalder R; Mamot C; Hasler-Strub U; Rochlitz C; Mueller A; Berset C; Wiliders H; Perey L; Rudolf CB; Hawle H; Rondeau S; Neven P
    Eur J Cancer; 2015 Jul; 51(10):1212-20. PubMed ID: 25892646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
    J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
    Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
    J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.